Vir Biotechnology Receives FDA Breakthrough Therapy ...
Vir Biotechnology's tobevibart and elebsiran received FDA Breakthrough Therapy and EMA PRIME designations for chronic hepatitis delta treatment, based on Phase 2 SOLSTICE trial data showing rapid virus suppression. The Phase 3 ECLIPSE program starts in 2025, aiming to expedite development for this serious condition with unmet medical needs.
Reference News
Vir Biotechnology Receives FDA Breakthrough Therapy ...
Vir Biotechnology's tobevibart and elebsiran received FDA Breakthrough Therapy and EMA PRIME designations for chronic hepatitis delta treatment, based on Phase 2 SOLSTICE trial data showing rapid virus suppression. The Phase 3 ECLIPSE program starts in 2025, aiming to expedite development for this serious condition with unmet medical needs.